Impact of patient's specification on clinical outcome for an I-131 ablation therapy with differentiated thyroid carcinoma.

被引：0

作者：

Nakayama, M. ^{[1
]}

Okizaki, A. ^{[1
]}

Sakaguchi, M. ^{[2
]}

Uno, T. ^{[2
]}

Sato, J. ^{[2
]}

Ishitoya, S. ^{[1
]}

机构：

[1] Asahikawa Med Univ, Dept Radiol, Asahikawa, Hokkaido, Japan

[2] Asahikawa Med Univ Hosp, Radiol Technol Sect, Asahikawa, Hokkaido, Japan

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：S353 / S353

页数：1

共 50 条

[11] The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation
Watanabe, Ken
Uchiyama, Mayuki
Fukuda, Kunihiko
JAPANESE JOURNAL OF RADIOLOGY, 2017, 35 (09) : 505 - 510
[12] Predicting factors of successful postsurgical remnant ablation with I-131 in patients with differentiated thyroid carcinoma
Fallahi, B.
Beiki, D.
Takavar, A.
Eftekhari, M.
Fard-Esfahani, A.
Gilani, K. Ansari
Saghari, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S320 - S320
[13] The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation
Ken Watanabe
Mayuki Uchiyama
Kunihiko Fukuda
Japanese Journal of Radiology, 2017, 35 : 505 - 510
[14] I-131 ablation therapy in patients with differentiated thyroid cancer: efficacy of different therapeutic protocols
Salvatori, M
Rufini, V
Leccisotti, L
Perotti, G
Maussier, ML
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S465 - S465
[15] Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma
Taube, A
Lundell, G
CANCER, 1997, 79 (01) : 190 - 190
[16] Thyroid remnant I-131 ablation for papillary and follicular thyroid carcinoma
Mazzaferri, EL
THYROID, 1997, 7 (02) : 265 - 271
[17] Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma
Bal, C
Padhy, AK
Jana, S
Pant, GS
Basu, AK
CANCER, 1996, 77 (12) : 2574 - 2580
[18] I-131 ABLATION THERAPY FOR A PATIENT ON MAINTENANCE HEMODIALYSIS
HOWARD, N
GLASSER, M
BRITISH JOURNAL OF RADIOLOGY, 1981, 54 (639): : 259 - 259
[19] The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy
Sengoz, Tarik
Surucu, Erdem
Demir, Yusuf
Derebek, Erkan
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2012, 21 (03) : 103 - 109
[20] Factors influencing the dosimetry and the therapeutic outcome of radioiodine (I-131) therapy of differentiated thyroid cancer
Behr, TM
Behe, M
Gratz, S
Hüfner, M
Becker, W
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1004 - 1004

← 1 2 3 4 5 →